Targeting the EGFR pathway: An alternative strategy for the treatment of tuberous sclerosis complex?
Julia SchachenhoferVictoria-Elisabeth GruberStefanie Valerie FehrerCarmen HaiderSarah GlatterEwa LiszewskaRomana HöftbergerEleonora AronicaKarl RösslerJacek JaworskiTheresa SchollMartha FeuchtPublished in: Neuropathology and applied neurobiology (2024)
Our study demonstrates that EGFR suppression might be an effective alternative treatment option for SEGAs and tubers, as well as other mTOR-associated malformations of cortical development, including FCD2B.